We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus
Read MoreHide Full Article
Key Takeaways
SMMT Q3 loss was narrower than expected, with lower G&A expenses offsetting increased R&D spending.
Summit secured a $2 billion strategic equity investment from AstraZeneca following the quarter's end.
AstraZeneca and Daiichi Sankyo partner with Summit to evaluate ivonescimab combinations across solid tumors.
Summit Therapeutics (SMMT - Free Report) incurred a third-quarter 2026 loss per share of 26 cents, narrower than the Zacks Consensus Estimate of a loss of 28 cents per share. In the year-ago period, the company had recorded a loss of 31 cents per share.
The company currently lacks a marketed product in its portfolio. As a result, it did not record revenues in the quarter.
More on SMMT’s Q3 Results
Research and development (R&D) expenses increased 29% year over year to $169.1 million. The increase primarily reflected higher clinical development costs associated with the expansion of ivonescimab studies.
General and administrative (G&A) expenses plunged 55.9% year over year to $45.5 million, primarily due to lower stock-based compensation expenses.
As of Sept. 30, 2026, Summit had cash, cash equivalents and short-term investments totaling $629.8 million compared with $690.7 million as of June 30, 2026.
During the third quarter, Summit raised $94.1 million in gross proceeds through its at-the-market facility. In October, AstraZeneca (AZN - Free Report) completed a $2 billion strategic equity investment in Summit to support the continued development of ivonescimab.
Year to date, shares of SMMT have lost 7.5% compared with the industry’s 3.4% decline.
Image Source: Zacks Investment Research
Updates on SMMT’s Lung Cancer Portfolio
The lead candidate in Summit's pipeline is ivonescimab, a dual PD-1/VEGF inhibitor being developed in collaboration with China-based Akeso. The drug is being evaluated across several solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), bladder cancer and kidney cancer. Ivonescimab is currently approved only in China for three distinct NSCLC indications.
Earlier this year, the FDA accepted the company's biologics license application seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutant, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with third-generation EGFR-TKIs. A final decision is expected by Nov. 14, 2026.
Summit continues advancing the phase III HARMONi-3 study evaluating ivonescimab plus chemotherapy against Merck’s (MRK - Free Report) blockbuster PD-L1 drug Keytruda (pembrolizumab) plus chemotherapy in first-line metastatic NSCLC. Enrollment has been completed in squamous and non-squamous cohorts. The company is conducting the phase III HARMONi-7 study of ivonescimab monotherapy in first-line metastatic NSCLC patients with high PD-L1 expression. Enrollment is expected to be completed in 2027.
SMMT's Recent Expansion Into Other Cancers
Summit expanded ivonescimab's development into bladder cancer through the phase II/III HARMONi-GU1 study, which began site activation and enrollment in August. The study evaluates ivonescimab combined with Astellas Pharma/Pfizer’s Padcev (enfortumab vedotin) against Merck’s Keytruda (pembrolizumab) plus Padcev as a first-line treatment for advanced urothelial carcinoma.
Meanwhile, the phase III HARMONi-GI3 study evaluating the candidate in combination with chemotherapy against bevacizumab plus chemotherapy in first-line metastatic CRC, continues enrolling patients, with enrollment expected to conclude in the third quarter of 2027.
Summit's Expanding Oncology Collaborations
Summit is entering into collaborations to explore ivonescimab in additional cancer types. In September, it partnered with AstraZeneca to study ivonescimab in combination with the investigational drug sonesitatug vedotin in gastrointestinal cancers.
In October, Summit entered into another collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab with Datroway in solid tumors. The collaboration is expected to begin with a phase III study in first-line triple-negative breast cancer.
Summit also partnered with the ECOG-ACRIN Cancer Research Group to study ivonescimab in first-line advanced biliary tract cancer. The phase II/III study will compare ivonescimab plus chemotherapy with two existing treatment combinations: Merck’s Keytruda plus chemotherapy and AstraZeneca’s Imfinzi plus chemotherapy.
Summit Therapeutics PLC Price, Consensus and EPS Surprise
View the Zacks #1 Rank List
Image: Bigstock
SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus
Key Takeaways
Summit Therapeutics (SMMT - Free Report) incurred a third-quarter 2026 loss per share of 26 cents, narrower than the Zacks Consensus Estimate of a loss of 28 cents per share. In the year-ago period, the company had recorded a loss of 31 cents per share.
The company currently lacks a marketed product in its portfolio. As a result, it did not record revenues in the quarter.
More on SMMT’s Q3 Results
Research and development (R&D) expenses increased 29% year over year to $169.1 million. The increase primarily reflected higher clinical development costs associated with the expansion of ivonescimab studies.
General and administrative (G&A) expenses plunged 55.9% year over year to $45.5 million, primarily due to lower stock-based compensation expenses.
As of Sept. 30, 2026, Summit had cash, cash equivalents and short-term investments totaling $629.8 million compared with $690.7 million as of June 30, 2026.
During the third quarter, Summit raised $94.1 million in gross proceeds through its at-the-market facility. In October, AstraZeneca (AZN - Free Report) completed a $2 billion strategic equity investment in Summit to support the continued development of ivonescimab.
Year to date, shares of SMMT have lost 7.5% compared with the industry’s 3.4% decline.
Image Source: Zacks Investment Research
Updates on SMMT’s Lung Cancer Portfolio
The lead candidate in Summit's pipeline is ivonescimab, a dual PD-1/VEGF inhibitor being developed in collaboration with China-based Akeso. The drug is being evaluated across several solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), bladder cancer and kidney cancer. Ivonescimab is currently approved only in China for three distinct NSCLC indications.
Earlier this year, the FDA accepted the company's biologics license application seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutant, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with third-generation EGFR-TKIs. A final decision is expected by Nov. 14, 2026.
Summit continues advancing the phase III HARMONi-3 study evaluating ivonescimab plus chemotherapy against Merck’s (MRK - Free Report) blockbuster PD-L1 drug Keytruda (pembrolizumab) plus chemotherapy in first-line metastatic NSCLC. Enrollment has been completed in squamous and non-squamous cohorts. The company is conducting the phase III HARMONi-7 study of ivonescimab monotherapy in first-line metastatic NSCLC patients with high PD-L1 expression. Enrollment is expected to be completed in 2027.
SMMT's Recent Expansion Into Other Cancers
Summit expanded ivonescimab's development into bladder cancer through the phase II/III HARMONi-GU1 study, which began site activation and enrollment in August. The study evaluates ivonescimab combined with Astellas Pharma/Pfizer’s Padcev (enfortumab vedotin) against Merck’s Keytruda (pembrolizumab) plus Padcev as a first-line treatment for advanced urothelial carcinoma.
Meanwhile, the phase III HARMONi-GI3 study evaluating the candidate in combination with chemotherapy against bevacizumab plus chemotherapy in first-line metastatic CRC, continues enrolling patients, with enrollment expected to conclude in the third quarter of 2027.
Summit's Expanding Oncology Collaborations
Summit is entering into collaborations to explore ivonescimab in additional cancer types. In September, it partnered with AstraZeneca to study ivonescimab in combination with the investigational drug sonesitatug vedotin in gastrointestinal cancers.
In October, Summit entered into another collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab with Datroway in solid tumors. The collaboration is expected to begin with a phase III study in first-line triple-negative breast cancer.
Summit also partnered with the ECOG-ACRIN Cancer Research Group to study ivonescimab in first-line advanced biliary tract cancer. The phase II/III study will compare ivonescimab plus chemotherapy with two existing treatment combinations: Merck’s Keytruda plus chemotherapy and AstraZeneca’s Imfinzi plus chemotherapy.
Summit Therapeutics PLC Price, Consensus and EPS Surprise
Summit Therapeutics PLC price-consensus-eps-surprise-chart | Summit Therapeutics PLC Quote
SMMT’s Zacks Rank
Summit currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.